Oncology Drugs: Medicare Part D Spending

• 68medicines with Part D spending (calendar year 2024)

Each number has its full source under its own list below.

1. 1Humira(Cf) PenAdalimumab · $3,531.42 per unit$4.3 billion
2. 2Humira PenAdalimumab · $3,351.33 per unit$697.4 million
3. 3OrgovyxRelugolix · $87.04 per unit$484.3 million
4. 4Humira(Cf)Adalimumab · $3,407.72 per unit$400.9 million
5. 5HumiraAdalimumab · $3,377.97 per unit$208.9 million
6. 6Lupron DepotLeuprolide Acetate · $5,177.85 per unit$164 million
7. 7LorbrenaLorlatinib · $485.61 per unit$116.7 million
8. 8Ondansetron ODTOndansetron · $0.50 per unit$72.9 million
9. 9Ondansetron HCl*Ondansetron HCl · $0.45 per unit$68.9 million
10. 10Humira(Cf) Pen Crohn'S-Uc-HsAdalimumab · $6,829.98 per unit$59.2 million
11. 11Cyltezo(Cf) PenAdalimumab-Adbm · $3,440.74 per unit$52.7 million
12. 12Sunitinib MalateSunitinib Malate · $246.26 per unit$43.8 million
13. 13Amjevita(Cf) AutoinjectorAdalimumab-Atto · $1,063.26 per unit$36.9 million
14. 14AnastrozoleAnastrozole · $0.29 per unit$32.1 million
15. 15RubracaRucaparib Camsylate · $144.47 per unit$31.5 million

Source: Centers for Medicare & Medicaid Services, Medicare Part D Spending by Drug, calendar year 2024. Retrieved 12 Nov 2026.

• Early deaths from long-term diseases (WHO)
• Clinical trials: Cancer
• Cancer death rate

• Women's health
• Smoking
• Cell and gene therapy
• Respiratory
• HIV
• Bones and joints
• Brain and nerves
• Pediatric
• Gut health
• Hepatitis